Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    SELECT Proves Semaglutide 2.4 mg CV Benefit at AHA 2023

    SELECT Proves Semaglutide 2.4 mg CV Benefit at AHA 2023

    FromDiabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

    Start listeningView podcast show

    SELECT Proves Semaglutide 2.4 mg CV Benefit at AHA 2023

    FromDiabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

    ratings:
    Length:
    16 minutes
    Released:
    Nov 11, 2023
    Format:
    Podcast episode

    Description

    In this episode, hosts take a deep dive into the study’s results, including secondary endpoints, and what it means for the care of patients with overweight or obesity and preexisting cardiovascular disease in real-world settings.
    Released:
    Nov 11, 2023
    Format:
    Podcast episode

    Titles in the series (94)

    Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at http://HCPLive.com/Clinical/Endocrinology. Please direct podcast-related inquiries to PCampbell@MJHLifesciences.com. Editor's note: Episodes predating January 2023 were hosted by Endocrinology Network. Episodes predating March 2022 were titled The Endocrine Outlook.